Smallpox primary prevention
|
Smallpox Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Smallpox primary prevention On the Web |
|
American Roentgen Ray Society Images of Smallpox primary prevention |
|
Risk calculators and risk factors for Smallpox primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Primary Prevention
The administration of the vaccine can attenuate, sometimes prevent, the manifestations of smallpox.[1] The vaccine is given in the upper arm, using a bifurcated needle that is dipped into the vaccine solution. When removed, the needle retains a droplet of the vaccine. The needle is used to prick the skin a number of times in a few seconds. The pricking is not deep, reaching basilar epithelium, but it will cause a sore spot and one or two droplets of blood will be formed.
If the vaccination is successful a cellular reaction will then develop, leading to the formation of the Jennerian pustule (1-2 cm), a major reaction. The Jennerian pustule is a sign of successful vaccination and leads to full immunity in more than 95%, possibly for 5 to 10 years.
Below is the progression of the appearance of the local of administrations of the vaccine: a red and itchy bump develops at the vaccine site in three or four days. In the first week, the bump becomes a large blister, fills with pus, and begins to drain. During the second week, the blister begins to dry up and a scab is formed. The scab falls off in the third week, leaving a small scar.
It is important to notice that people who were vaccinated prior to 1972, in case of revaccination, may experience accelerated immune response.
Vaccine Generation
Since smallpox was considered eradicated, vaccination is not advised for common citizens. The only people with formal indication for Vaccinia vaccine are the laboratory or clinical individuals who work with the virus at specialized laboratories.[1]
Three generations of vaccines have been developed so far:
- 1st generation - a mixture of related viruses, which differ from the remaining orthopoxviruses. Reactions to these generation included:[1][2][3]
- Regional swelling
- Painful lymphadenitis
- 2nd generation - individual vaccinia clones, derived from viruses which are genetically similar, to the ones that made the 1st generation vaccine. More efficient production of the vaccine.[3][4]
- 3rd generation - developed from the attenuated vaccinia strains, after genetic manipulation or multiple passage through non-human tissue. Contain strains not as virulent as previous generations, and therefore safer, mainly because of an delay in replication of the virus.[3][4][5][6]
Vaccine Recommendations
Vaccine Adverse Events
The following adverse events to the vaccine were reported:[3][7][8][9]
- Fetal vaccinia
- Progressive vaccinia
- Generalized vaccinia
- Non-specific rashes
- Eczema vaccinatum
- Encephalitis
- Myopericarditis
Vaccine Contraindications
In the absence of reintroduction of smallpox, vaccination is contraindicated in the following:[3][10]
- Patients with allergy to vaccine components
- History of atopic dermatitis
- History of exfoliative skin disorders
- Inflammatory eye disorders
- Immunosuppressed patients
- Heart disease
- Pregnancy
- Disease cases in the family
- Children <1 year
- Breastfeeding
Post-Vaccination
After vaccination, it is important to follow care instructions for the site of the vaccine. Because the virus is live, it can spread to other parts of the body, or to other people. The vaccinia virus (the live virus in the smallpox vaccine) may cause rash, fever, and head and body aches. In certain groups of people, complications from the vaccinia virus can be severe.
Vaccine Benefit
Vaccination within 3 days of exposure will prevent or significantly lessen the severity of smallpox symptoms in the vast majority of people. Vaccination 4 to 7 days after exposure likely offers some protection from disease or may modify the severity of disease.
Vaccine
The chart below describes a patient that appears to show an adverse reaction to the smallpox vaccine and the protocol involved with it.
References
- ↑ 1.0 1.1 1.2 Breman, Joel G.; Henderson, D.A. (2002). "Diagnosis and Management of Smallpox". New England Journal of Medicine. 346 (17): 1300–1308. doi:10.1056/NEJMra020025. ISSN 0028-4793.
- ↑ ROBERTS JA (1962). "Histopathogenesis of mousepox. I. Respiratory infection". Br J Exp Pathol. 43: 451–61. PMC 2095140. PMID 13974310.
- ↑ 3.0 3.1 3.2 3.3 3.4 Moore, Zack S; Seward, Jane F; Lane, J Michael (2006). "Smallpox". The Lancet. 367 (9508): 425–435. doi:10.1016/S0140-6736(06)68143-9. ISSN 0140-6736.
- ↑ 4.0 4.1 Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH; et al. (2004). "Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox". Nature. 428 (6979): 182–5. doi:10.1038/nature02331. PMID 15014500.
- ↑ Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG; et al. (2001). "Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques". Vaccine. 19 (27): 3700–9. PMID 11395204.
- ↑ Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI; et al. (1992). "NYVAC: a highly attenuated strain of vaccinia virus". Virology. 188 (1): 217–32. PMID 1566575.
- ↑ Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA; et al. (2003). "Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel". JAMA. 289 (24): 3283–9. doi:10.1001/jama.289.24.3283. PMID 12824210.
- ↑ Arness, M. K. (2004). "Myopericarditis following Smallpox Vaccination". American Journal of Epidemiology. 160 (7): 642–651. doi:10.1093/aje/kwh269. ISSN 0002-9262.
- ↑ Chen RT, Lane JM (2003). "Myocarditis: the unexpected return of smallpox vaccine adverse events". Lancet. 362 (9393): 1345–6. doi:10.1016/S0140-6736(03)14674-0. PMID 14585633.
- ↑ "Recommendations for Using Smallpox Vaccine in a Pre-Event Vaccination Program".